Followers | 91 |
Posts | 3296 |
Boards Moderated | 0 |
Alias Born | 10/18/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 16, 2020 1:56:11 PM
The company's preparing to ship a product that hasn't even begun late-stage testing.
Cory Renauer
Cory Renauer
(TMFang4apples)
Jul 16, 2020 at 1:38PM
Author Bio
The race to develop a coronavirus vaccine is moving forward rapidly, and some drugmakers have taken an unusual step to rapidly deploy their respective vaccines the moment the Food and Drug Administration gives the green light. Moderna (NASDAQ:MRNA) is the latest drugmaker to begin manufacturing millions of doses of its still-experimental vaccine, mRNA-1273, at risk.
During a recent conference call to discuss encouraging phase 1 trial results for mRNA-1273, CEO Stephane Bancel sketched out a plan to produce enough doses to vaccinate everybody in the U.S. In fact, the company thinks it can produce between 500 million and 1 billion doses annually. At the moment, Moderna and its manufacturing partners are producing doses of mRNA-1273 at three sites for the U.S. market.
Vials labeled as containing cronavirus vaccine and a stack of cash.
IMAGE SOURCE: GETTY IMAGES.
During a phase 1 clinical trial, all 45 patients had antibodies in their bloodstream produced in response to mRNA-1273. But the immune system produces lots of different antibodies when it encounters anything foreign, so unfortunately it's hard to draw any meaningful conclusions from the results.
Volunteers vaccinated with mRNA-1273 produced high levels of some antibodies also seen in patients that have recovered from COVID-19. But we still have no idea whether or not high concentrations of those antibodies will effectively prevent SARS-CoV-2 from spreading.
By the end of July, Moderna plans to begin a 30,000-patient phase 3 study with mRNA-1273 that was previously scheduled to begin on July 9. The pivotal study was delayed because the company was late to submit final protocol changes to the FDA. The delay puts mRNA-1273 behind AZD1222 from AstraZeneca (NYSE:AZN), another coronavirus vaccine candidate that began a 5,000-patient phase 3 trial in Brazil at the end of June.
Recent MRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 04:45:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:05:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 07:16:06 PM
- Apple Showcases AI at WWDC 2024, Nvidia Stock Split Starts Today, and More News • IH Market News • 06/10/2024 11:29:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:27:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:20:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:12:54 PM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:36:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:20:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:11:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:36:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:27:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 08:16:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 08:12:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:22:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:20:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:14:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:12:39 PM
- Robinhood Shares Surge 3.3% on Stock Buyback Announcement; Anglo Declines BHP Deadline Extension, and More News • IH Market News • 05/29/2024 11:34:18 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 07:21:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 07:21:45 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM